Home » Somahlution Reveals Positive Study Results Showing Efficacy of DuraGraft
Somahlution Reveals Positive Study Results Showing Efficacy of DuraGraft
Somahlution’s DuraGraft vascular graft treatment significantly improves long-term outcomes in coronary artery bypass grafting (CABG) surgery, the company said at the European Association for Cardio-Thoracic Surgery (EACTS) annual meeting.
DuraGraft treatment for 2,436 patients who underwent CABG surgery has shown statistically significant lower risks for non-fatal myocardial infarction, repeat revascularization, and a composite of all major adverse cardiac events.
DuraGraft is currently not available in the U.S. market. — Cynthia Jessup
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May